The Lead Episode 105: A Discussion of Acute Safety and Effectiveness of a Novel Balloon-Based PFA Catheter in Paroxysmal and Persistent AF: Acute Results of the Volt-AF IDE Trial (Live at HRS 2025)-The Lead Episode 105 Speaker Information

The Lead Episode 105 Speaker Information

Pdf Summary

The document presents an overview of a discussion led by Michael S. Lloyd, MD, at Emory University, regarding the acute safety and effectiveness of a new balloon-based Pulsed Field Ablation (PFA) catheter used in treating paroxysmal and persistent Atrial Fibrillation (AF). This discussion centers on the initial outcomes from the Volt-AF IDE Trial and has been published in the Heart Rhythm Journal. <br /><br />The trial evaluated a novel catheter designed to improve the safety and effectiveness of AF treatments. Details concerning the catheter's performance, patient outcomes, and safety measures were presumably analyzed, although specific results and statistical data are not provided in the document.<br /><br />Contributors to the discussion included experts in cardiac electrophysiology: Christopher C. Cheung, MD, from Sunnybrook HSC, University of Toronto; and Edward P. Gerstenfeld, MD, from the University of California, San Francisco. The participants disclosed varying degrees of involvement with related industry companies like Medtronic, Boston Scientific, and Abbott Medical, which may have implications for potential biases in their discussion.<br /><br />In summary, the meeting aimed to provide insights into an innovative treatment option for AF, examining its immediate impacts on patient safety and wellbeing. The emphasis on acute results suggests a focus on short-term implications, providing foundational but preliminary information to support further investigation through extended trials.

Keywords

Pulsed Field Ablation

Atrial Fibrillation

Volt-AF IDE Trial

Balloon-based catheter

Heart Rhythm Journal

Cardiac electrophysiology

Michael S. Lloyd

Acute safety

Patient outcomes

Industry involvement